Janine Mansi

Guy's and St Thomas' NHS Foundation Trust — United Kingdom

Medicine · Health Sciences

52h-index11.2kcitations196works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(41), Breast Cancer Treatment Studies(34), Cancer Treatment and Pharmacology(34), Advanced Breast Cancer Therapies(29), Estrogen and related hormone effects(15)

Publications195 total

Alpelisib-Induced Late-Onset Diabetic Ketoacidosis in Advanced Breast Cancer
Diabetes Care·2025Open Access
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
Nature Communications·2025· 1 citedOpen Access
The Perceptions of Patients, Carers and Clinicians Relating to SACT Decision‐Making in Older People With Cancer: Qualitative Findings From the Electronic Frailty Index (eFI) in Cancer Study
European Journal of Cancer Care·2025Open Access
100 Cancer Research UK (CRUK) National Standardised Regimen-Specific Non-Small Cell Lung Cancer (NSCLC) Consent Forms for Systemic Anti-Cancer Therapies (SACT): Where Are We Now?
Lung Cancer·2024
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
Nature Communications·2023Open Access
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
Nature Communications·2023· 54 citedOpen Access
Electronic frailty index predicts 30-day mortality from chemotherapy in breast, colorectal and lung cancer.
Journal of Clinical Oncology·2023· 2 cited
Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials
The Lancet·2023· 169 citedOpen Access
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial
European Journal of Cancer·2023· 27 citedOpen Access
Concept: A randomised multicentre trial of first line chemotherapy comparing three weekly cabazitaxel versus weekly paclitaxel in HER2 negative metastatic breast cancer
The Breast·2022· 7 citedOpen Access
The HERPET study: Imaging HER2 expression in breast cancer with the novel PET tracer [<sup>18</sup>F]GE-226, a first-in-patient study.
Journal of Clinical Oncology·2022· 4 cited
Abstract GS3-10: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)
Cancer Research·2022· 6 cited
Use of Cancer Research UK (CRUK) national standardised regimen specific lung consent forms for systemic anti-cancer therapies (SACT)
Lung Cancer·2022
The presenting dental status of solid tumours with bone metastases requiring bone-targeting agents - part 2: breast cancer
BDJ·2022· 7 cited
265P Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)
Annals of Oncology·2021· 8 cited
Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer
JAMA Oncology·2021· 43 citedOpen Access
Randomized multicenter trial of 3 weekly cabazitaxel versus weekly paclitaxel chemotherapy in the first-line treatment of HER2 negative metastatic breast cancer (MBC).
Journal of Clinical Oncology·2021· 2 cited
45P Long-term efficacy of neratinib in HER2-positive early-stage breast cancer: Overall survival and central nervous system outcomes from the phase III ExteNET trial
Annals of Oncology·2021
Abstract PD3-03: Continued efficacy of neratinib in patients with HER2-positive early-stage breast cancer: Final overall survival analysis from the randomized phase 3 ExteNET trial
Cancer Research·2021· 5 cited
Abstract PS9-11: Health-related quality of life for margetuximab + chemotherapy vs. trastuzumab + chemotherapy in the phase 3 SOPHIA trial of patients with pretreated HER2+ metastatic breast cancer
Cancer Research·2021
page 1 of 10Next →

Frequent Co-authors

R. Charles Coombes(9), Judith M. Bliss(7), David Cunningham(6), Tamas Hickish(6), U Berger(6), Ian E. Smith(5), Helena Earl(5), Kay W. Colston(5), Andrew Wardley(4), Miguel Martín(4), Bent Ejlertsen(4), Michael Gnant(4), J.-C. Gazet(4), Karen McAdam(4), Daniel Rea(4), David Cameron(4), Michelle Guy(4), Robert Leonard(4), K W Colston(4), Peter Harper(3)